Harbour BioMed Reports Results of Phase Ib Clinical Trial of Porustobart in Combination of Toripalimab in Patients with Hepatocellular Carcinoma at ASCO 2023

  Porustobart in combination of toripalimab showed promising anti-tumor activity Porustobart in combination of toripalimab showed acceptable safet...

Harbour BioMed Reports Full Year 2022 Financial Results

CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands, April 3, 2023 /PRNewswire/ -- Harbour BioMed ("HBM" or...

Harbour BioMed Announces Positive Topline Results from Phase III Trial of Batoclimab for Treatment of Generalized Myasthenia Gravis

Cambridge, MA, Rotterdam, NL, Suzhou, CN – March 6, 2023   Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...

Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed

CAMBRIDGE, Mass., February 14, 2023   Cullinan Oncology, Inc. (Nasdaq: CGEM) and Harbour BioMed (HKEX: 02142) today announced that Cullinan Onc...

Harbour BioMed Announces IND Clearance for Novel G Protein-coupled Receptor HBM1022 Targeting CCR8 in the U.S.

HBM1022 is a monoclonal antibody generated from Harbour BioMed’s integrated G protein-coupled receptor (GPCR) platform HBM1022 presented cynomolgus ...

HBM Alpha Therapeutics Raises Seed Round to Advance Next-Gen Therapies for Endocrine Disorders

Cambridge, MA, January 26, 2023   HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company incubated by Harbour BioMed (HKEX: 02142...

Harbour BioMed Announces IND Clearance for HBM1007 Targeting CD73 in the U.S.

HBM1007 is a fully-human monoclonal antibody targeting CD73 HBM1007 is generated from Harbour Mice®  H2L2 platform With unique epitopes to...

Harbour BioMed Announces IND Clearance for First-in-Class Anti-B7H7 (HHLA2) Antibody by the U.S. FDA

HBM1020 is the globally first-in-class fully human monoclonal antibody targeting B7H7. HBM1020 is also the globally first-ever monoclonal antibody targeti...

Harbour BioMed Reports the Latest Progress from Phase I Clinical Trial of Porustobart in Combination with Toripalimab in Advanced Melanoma

Cambridge, MA, Rotterdam, NL, Suzhou, CN— December 8, 2022   Harbour BioMed (the “Company”, HKEX: 02142), today announced the pro...

Invitation | Harbour BioMed Investor Day 2022